SubHero Banner
Text

Repatha® (evolocumab) – New indication and expanded indication

September 24, 2021 - Amgen announced the FDA approval of Repatha (evolocumab), as an adjunct to diet and other low density lipoprotein-cholesterol (LDL-C)-lowering therapies in pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.

Download PDF